Everolimus, approved by the FDA as a mammalian target of rapamycin (mTOR) inhibitor, is used as a second-line treatment for metastatic renal-cell carcinoma (RCC) resistant to sorafenib or sunitinib. The gene discussed is MTOR; the disease is renal cell carcinoma.